

Mustafa Saad Siddiqui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9476658/publications.pdf>

Version: 2024-02-01

28
papers

2,342
citations

516710

16
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

2913
citing authors

#	ARTICLE	IF	CITATIONS
1	AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. <i>Lancet Neurology</i> , The, 2011, 10, 309-319.	10.2	582
2	Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). <i>Movement Disorders</i> , 2011, 26, 90-99.	3.9	394
3	Prognostic Significance of Hypernatremia and Hyponatremia among Patients with Aneurysmal Subarachnoid Hemorrhage. <i>Neurosurgery</i> , 2002, 50, 749-756.	1.1	215
4	Aggressive Mechanical Clot Disruption and Low-dose Intra-arterial Third-generation Thrombolytic Agent for Ischemic Stroke: A Prospective Study. <i>Neurosurgery</i> , 2002, 51, 1319-1329.	1.1	196
5	Intracerebral Hemorrhages Associated With Neurointerventional Procedures Using a Combination of Antithrombotic Agents Including Abciximab. <i>Stroke</i> , 2002, 33, 1916-1919.	2.0	129
6	Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa. <i>Hypertension</i> , 2015, 65, 101-107.	2.7	125
7	Influence of Type 2 Diabetes on Brain Volumes and Changes in Brain Volumes. <i>Diabetes Care</i> , 2013, 36, 90-97.	8.6	113
8	Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. <i>Lancet Neurology</i> , The, 2020, 19, 491-501.	10.2	88
9	Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. <i>JCI Insight</i> , 2017, 2, e90133.	5.0	74
10	Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder. <i>NeuroImage</i> , 2011, 54, S247-S255.	4.2	72
11	A Case of Mania following Deep Brain Stimulation for Obsessive Compulsive Disorder. <i>Stereotactic and Functional Neurosurgery</i> , 2010, 88, 322-328.	1.5	66
12	Brain penetration effects of microelectrodes and deep brain stimulation leads in ventral intermediate nucleus stimulation for essential tremor. <i>Journal of Neurosurgery</i> , 2010, 112, 491-496.	1.6	51
13	Weight change following deep brain stimulation for movement disorders. <i>Journal of Neurology</i> , 2010, 257, 1293-1297.	3.6	41
14	Pseudobulbar affect: prevalence and quality of life impact in movement disorders. <i>Journal of Neurology</i> , 2010, 257, 1382-1387.	3.6	41
15	Inappropriate crying and laughing in Parkinson disease and movement disorders. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 234-240.	2.6	36
16	Application of the 5-2-1™ screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. <i>Neurodegenerative Disease Management</i> , 2020, 10, 309-323.	2.2	33
17	<sc>DUOGLOBE</sc>: One-Year Outcomes in a <sc>Real-World</sc> Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1061-1074.	1.5	22
18	Association between subthalamic nucleus deep brain stimulation and weight gain: Results of a case-control study. <i>Clinical Neurology and Neurosurgery</i> , 2016, 140, 38-42.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Analysis of the prevalence and onset of dysphonia and dysphagia symptoms in movement disorders at an academic medical center. <i>Journal of Clinical Neuroscience</i> , 2019, 64, 111-115.	1.5	12
20	Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. <i>Journal of Parkinson's Disease</i> , 2022, 12, 917-926.	2.8	9
21	North American survey on impact of the COVID-19 pandemic shutdown on DBS care. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 41-45.	2.2	8
22	Deep brain stimulation: Treating neurological and psychiatric disorders by modulating brain activity. <i>NeuroRehabilitation</i> , 2008, 23, 105-113.	1.3	6
23	Comparative Effectiveness of Carbidopa-Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson's Disease-Related Pill Burden Reduction in Advanced Parkinson's Disease: A Retrospective Real-World Cohort Study. <i>Neurology and Therapy</i> , 2022, 11, 851-861.	3.2	5
24	Comprehensive Evaluation of Voice-Specific Outcomes in Patients With Essential Tremor Before and After Deep Brain Stimulation. <i>Journal of Voice</i> , 2022, 36, 838-846.	1.5	3
25	Auditory-Perceptual Evaluation of Deep Brain Stimulation on Voice and Speech in Patients With Dystonia. <i>Journal of Voice</i> , 2020, 34, 636-644.	1.5	2
26	A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 2, 25-34.	0.9	2
27	Deep brain stimulation: treating neurological and psychiatric disorders by modulating brain activity. <i>NeuroRehabilitation</i> , 2008, 23, 105-113.	1.3	1
28	Deep Brain Stimulation: Patient Selection in Parkinson's Disease, Other Movement Disorders, and Neuropsychiatric Disorders. , 2008, , 83-98.		0